Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 9;9(5):e15991.
doi: 10.1016/j.heliyon.2023.e15991. eCollection 2023 May.

MicroRNA-372 acts as a double-edged sword in human cancers

Fatemeh Tajik  1 , Fatemeh Alian  2 , Mohammad Yousefi  3 , Ali Azadfallah  3 , Aref Hoseini  4 , Forogh Mohammadi  5 , Maryam Karimi-Dehkordi  6 , Shahin Alizadeh-Fanalou  7
Affiliations
Review

MicroRNA-372 acts as a double-edged sword in human cancers

Fatemeh Tajik et al. Heliyon. .

Abstract

MicroRNAs (miRNAs or miRs) are non-coding, single-stranded, endogenous RNAs that regulate various biological processes, most notably the pathophysiology of many human malignancies. It process is accomplished by binding to 3'-UTR mRNAs and controlling gene expression at the post-transcriptional level. As an oncogene, miRNAs can either accelerate cancer progression or slow it down as a tumor suppressor. MicroRNA-372 (miR-372) has been found to have an abnormal expression in numerous human malignancies, implying that the miRNA plays a role in carcinogenesis. It is both increased and downregulated in various cancers, and it serves as both a tumor suppressor and an oncogene. This study examines the functions of miR-372 as well as the LncRNA/CircRNA-miRNA-mRNA signaling pathways in various malignancies and analyses its potential prognostic, diagnostic, and therapeutic implications.

Keywords: Cancer; Function; Importance; MicroRNA-372; Oncogene; Tumor suppressor.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
The hairpin structure of pre-miR-372 and the sequence of mature miR-372-3p & -5p. The miR-372 gene is transcribed into a precursor (pre-miR-372) with 66 nucleotides in the nucleus, transferred to the cytoplasm by Exportin-5 for further processing to yield mature miRNAs with 23 nucleotides for mature miR-372-3p & -5p. The sequence of mature miR-372 is colored in red. The arrow indicates the orientations from 5′ to 3′. The codes of miR-372 were extracted from miRBase.
Fig. 2
Fig. 2
Effects of miR-372 on its target genes for regulating tumorigenesis biological behaviors. In the figure, all the target genes of miR-372 with tumorigenesis of human cancers have been shown. For example, miR-372 represses tumorigenesis by suppressing the PRKAC8 gene. In this regard, lncRNA-HULC inhibits the anti-tumor effect of miR-372. On the other hand, it has been reported that miR-372 via suppressing the FGF9 as well as activation of Wnt/B-Catenin and mtor signaling pathway leads to increased tumorigenesis biological behaviors.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer. 2006;6(11):857–866. - PubMed
    1. Siegel R.L., et al. Cancer statistics, 2021. CA A Cancer J. Clin. 2021;71(1):7–33. - PubMed
    1. Bray F., et al. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029–3030. - PubMed
    1. Sung H., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin. 2021;71(3):209–249. - PubMed
    1. Sahebi-Fakhrabad A., Sadeghi A.H., Handfield R. Evaluating state-level prescription drug monitoring program (PDMP) and pill mill effects on opioid consumption in pharmaceutical supply chain. Healthcare. 2023;11 doi: 10.3390/healthcare11030437. - DOI - PMC - PubMed